PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SignaBlok, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, received a Notice of Allowance of Key U.S. Patent for novel and first-in-class agents in sepsis and cancer - SignaBlok.com
SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer

 

NewswireToday - /newswire/ - Shrewsbury, MA, United States, 2013/07/01 - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, received a Notice of Allowance of Key U.S. Patent for novel and first-in-class agents in sepsis and cancer - SignaBlok.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

SignaBlok, Inc. today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering TREM-1 receptor-specific peptides for sepsis, cancer and other inflammation-associated indications. The allowed claims cover both product composition and treatment methods.

This application is the first patent application to issue, which broadly covers the Company's proprietary, first-in-class peptides, known as the SCHOOL peptides. The peptides target TREM-1, a specific receptor that serves as an inflammation amplifier and is critically involved in the pathogenesis of various cancers, sepsis, rheumatoid arthritis, and other inflammation-associated diseases.

"We are pleased that the USPTO has allowed this patent application, which will substantively expand the coverage of SignaBlok's intellectual property estate," said Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. "SignaBlok continues to develop novel intellectual property in the area of the SCHOOL technology that allows to block specific receptors in a new, ligand-independent manner. We have recently succeeded in the animal proof-of-concept testing of the SCHOOL technology in sepsis and lung cancer. Accordingly, we plan to consolidate key intellectual property required to develop and commercialize first-in-class therapies for these and other serious diseases with unmet clinical needs".

The new patent is expected to issue in the next few months.

About SignaBlok
SignaBlok (signablok.com) is developing a new class of therapies SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy.

SignaBlok Forward-Looking Statement
Various statements in this release concerning SignaBlok's future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. SignaBlok's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although SignaBlok's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by SignaBlok. Readers are cautioned not to rely on these forward-looking statements.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SignaBlok, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Alexander Sigalov - SignaBlok.com 
203-505-3807 sigalov[.]signablok.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SignaBlok, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SignaBlok, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)